tiprankstipranks
Impedimed Director Increases Stake Through Fee Conversion
Company Announcements

Impedimed Director Increases Stake Through Fee Conversion

Story Highlights
  • Impedimed is in the medical tech industry, focusing on non-invasive devices.
  • Director Andrew Grant increased his shares through fee conversion, boosting stakeholder confidence.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

Invest with Confidence:

Impedimed Limited ( (AU:IPD) ) has issued an update.

Impedimed Limited announced a change in the director’s interest, with Mr. Andrew Grant acquiring additional shares. The acquisition was a result of the issuance of shares in lieu of 30% of director fees for the quarter ended 31 December 2024, enhancing his total shareholding to 2,308,583 ordinary shares. This move signals a deeper alignment of the director’s interests with the company, potentially impacting stakeholder confidence positively.

More about Impedimed Limited

Impedimed Limited is a company involved in the medical technology industry, primarily focused on developing and providing non-invasive medical devices for measuring, monitoring, and managing fluid status and body composition.

YTD Price Performance: -2.50%

Average Trading Volume: 31,879

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $69.19M

For an in-depth examination of IPD stock, go to TipRanks’ Stock Analysis page.

Related Articles
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App